Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from LifeMD ( (LFMD) ) is now available.
LifeMD reported that for 2025 its revenue rose 25% to $194.1 million and adjusted EBITDA surged 309% to $15.3 million, while fourth-quarter revenue grew 4% to $46.9 million and adjusted EBITDA climbed 348% to $4.8 million. The company ended 2025 with $36.8 million in cash and no debt, launched oral Wegovy after year-end amid record GLP-1 weight-management sign-ups, expanded women’s and men’s health offerings, and issued 2026 guidance that anticipates double-digit revenue growth but front-loaded GLP-1 acquisition spending temporarily pressuring early-year profitability before EBITDA improves later in 2026.
LifeMD, Inc., based in New York and listed on Nasdaq as LFMD, is a provider of virtual primary care and specialty telehealth services, including weight management, men’s health under the Rex MD brand, and women’s health focused on menopause, hormonal and bone health. The company operates a 50-state medical benefits infrastructure, affiliated provider network and national pharmacy operation, targeting both self-pay and insurance-covered patients in the U.S. digital health market.
The most recent analyst rating on (LFMD) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.
Spark’s Take on LFMD Stock
According to Spark, TipRanks’ AI Analyst, LFMD is a Neutral.
The score is held down primarily by weak profitability and balance-sheet risk metrics in the provided financial statement analysis, plus a longer-term bearish technical setup (below 50/100/200-day averages and negative MACD). These are partially offset by constructive earnings-call guidance and operational momentum (telehealth growth and rising adjusted EBITDA) alongside improving cash flow.
To see Spark’s full report on LFMD stock, click here.
More about LifeMD
LifeMD, Inc., based in New York and listed on Nasdaq as LFMD, is a provider of virtual primary care and specialty telehealth services, including weight management, men’s health under the Rex MD brand, and women’s health focused on menopause, hormonal and bone health. The company operates a 50-state medical benefits infrastructure, affiliated provider network and national pharmacy operation, targeting both self-pay and insurance-covered patients in the U.S. digital health market.
LifeMD reported that for 2025 its revenue rose 25% to $194.1 million and adjusted EBITDA surged 309% to $15.3 million, while fourth-quarter revenue grew 4% to $46.9 million and adjusted EBITDA climbed 348% to $4.8 million. The company ended 2025 with $36.8 million in cash and no debt, launched oral Wegovy after year-end amid record GLP-1 weight-management sign-ups, expanded women’s and men’s health offerings, and issued 2026 guidance that anticipates double-digit revenue growth but front-loaded GLP-1 acquisition spending temporarily pressuring early-year profitability before EBITDA improves later in 2026.
Average Trading Volume: 1,045,329
Technical Sentiment Signal: Sell
Current Market Cap: $144.4M
For a thorough assessment of LFMD stock, go to TipRanks’ Stock Analysis page.